Works matching IS 10093419 AND DT 2022 AND VI 25 AND IP 7

Results: 17

Clinical Observation of Immunotherapy Efficacy and Adverse Effects in Chinese Patients with Lung Squamous Cell Carcinoma.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 546, doi. 10.3779/j.issn.1009-3419.2022.101.36

By:

Jiangyong YU;
Xiaonan WU;
Junling MA;
Xi CHEN;
Lin LI

Publication type:

Article

Research Progress of Antitumor Pharmacovigilance.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 541, doi. 10.3779/j.issn.1009-3419.2022.101.33

By:

Wenjuan SUN;
Yang HU;
Yan XU;
Bo ZHANG

Publication type:

Article

Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint Inhibitor Therapy.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 534, doi. 10.3779/j.issn.1009-3419.2022.101.28

By:

Liyuan DAI;
Xiaohong HAN

Publication type:

Article

Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 524, doi. 10.3779/j.issn.1009-3419.2022.101.29

By:

Chao GUO;
Jiaqi ZHANG;
Shanqing LI

Publication type:

Article

Advances in Diagnosis and Treatment of Leptomeningeal Metastasis of Lung Cancer.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 517, doi. 10.3779/j.issn.1009-3419.2022.101.25

By:

Naisheng GAO;
Tao XIN

Publication type:

Article

Challenges of Investigator-initiated Clinical Trials to Support the New Drug Development.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 511, doi. 10.3779/j.issn.1009-3419.2022.101.31

By:

Hua BAI;
Shuyang ZHANG

Publication type:

Article

Discussion on the Focus of On-site Inspection of Clinical Trials of Lung Cancer Targeted Therapy and Immunotherapy Drugs.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 506, doi. 10.3779/j.issn.1009-3419.2022.101.32

By:

Meng LI;
Lijing XU;
Xiuli LI;
Rong GAO

Publication type:

Article

The Role and Function of Clinical Research Nurses in Anti-tumor Drug Clinical Trials for Lung Cancer Patients.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 501, doi. 10.3779/j.issn.1009-3419.2022.101.30

By:

Fujie HAO;
Qin ZHU;
Sue WANG;
Ya LIU;
Lin JIANG;
Ruili PAN

Publication type:

Article

nalysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 493, doi. 10.3779/j.issn.1009-3419.2022.101.26

By:

Jingjing WANG;
Yujia CHI;
Hanxiao CHEN;
Bo JIA;
Xiaoyu ZHAI;
Menglei MA;
Jianjie LI;
Minglei ZHUO

Publication type:

Article

Application of MIDD in Clinical Research of Antitumor Drugs.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 487, doi. 10.3779/j.issn.1009-3419.2022.101.38

By:

Mengyang YU;
Hongyun WANG

Publication type:

Article

Opportunities and Challenges of RNA Interference Therapeutics in Oncology.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 482, doi. 10.3779/j.issn.1009-3419.2022.101.20

By:

Rui CHEN;
Yan XU

Publication type:

Article

Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 477, doi. 10.3779/j.issn.1009-3419.2022.101.19

By:

Lin JIANG;
Jingbo ZHANG;
Jiaqi HU;
Haixiang QI;
Heng XU

Publication type:

Article

Current Progress and Future Developments of Antibody Drug Conjugates in Lung Cancer.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 468, doi. 10.3779/j.issn.1009-3419.2022.101.22

By:

Yixiang ZHU;
Zhijie WANG

Publication type:

Article

Blocking Adenosine/A2AR Pathway for Cancer Therapy.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 460, doi. 10.3779/j.issn.1009-3419.2022.101.24

By:

Jia LIU;
Yuequan SHI;
Xiaoyan LIU;
Dongming ZHANG;
Yu BAI;
Yan XU;
Mengzhao WANG

Publication type:

Article

MUC16: The Novel Target for Tumor Therapy.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 452, doi. 10.3779/j.issn.1009-3419.2022.101.31

By:

Ruyun GAO;
Ning LOU;
Xiaohong HAN;
Yuankai SHI

Publication type:

Article

Consideration on the Research and Development of New Drugs for Rare Tumors.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 448, doi. 10.3779/j.issn.1009-3419.2022.101.27

By:

Ling TANG;
Yuanyuan SONG;
Zhimin YANG

Publication type:

Article

Considerations on Clinical Development and Regulatory of the Oversea License-in Anti-tumor Drugs.

Published in:

Chinese Journal of Lung Cancer, 2022, v. 25, n. 7, p. 443, doi. 10.3779/j.issn.1009-3419.2022.101.26

By:

Xiao ZHAO;
Ruimin HAO;
Xin TONG;
Limin ZOU;
Ling TANG;
Hong ZHANG;
Lin XIA;
Zhimin YANG

Publication type:

Article